Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Connect Biopharma Holdings (CNTB)
NASDAQ:CNTB
RESEARCH TOOLSreports
Holding CNTB?
Track your performance easily
CNTB Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$0.68 - $2.66
Previous Close$0.98
Volume32.26K
Average Volume (3M)29.49K
Market Cap
$52.05M
Enterprise Value-$64.15M
Total Cash (Recent Filing)¥118.65M
Total Debt (Recent Filing)¥465.00K
Price to Earnings (P/E)―
Beta0.44
Next Earnings
Mar 27, 2025EPS Estimate
-$0.32Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.58
Shares Outstanding55,102,954
10 Day Avg. Volume19,007
30 Day Avg. Volume29,494
Standard Deviation0.29
R-Squared0.00251
Alpha-0.01
Financial Highlights & Ratios
Price to Book (P/B)0.57
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$8.00Price Target Upside749.26% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
Connect Biopharma Holdings News
PremiumCompany Announcements
Connect Biopharma Welcomes New Finance VP
PremiumCompany Announcements
Connect Biopharma Pivots to U.S. Market Strategy
PremiumCompany Announcements
Connect Biopharma Executives Transition to New Roles
PremiumCompany Announcements
Connect Biopharma Unveils New Incentive Award Plan
PremiumCompany Announcements
Connect Biopharma Triumphs with Rademikibart TrialsBulls Say, Bears Say
Bulls Say
Financial MilestonesConnect Bio stands to receive up to $120 million in milestones for rademikibart in China, along with low double-digit royalties on sales.
Partnership OpportunitiesPositive clinical data in various indications could enhance the attractiveness of rademikibart for potential partnerships.
Regulatory ApprovalThe FDA agreed that the Phase 2 data supports advancing to Phase 3, indicating regulatory confidence in the drug's potential.
Bears Say
Capital RaisingThe company noted it would need to raise significant dilutive capital to support such studies, which may not make the most strategic sense at this stage.
Financial BurdenThese Phase 3 studies would require significant capital to run, which is estimated to cost around $150-200 million.
Strategic ConcernsThe company noted it would need to raise significant dilutive capital to support such studies, which may not make the most strategic sense at this stage.
---
Ownership Overview
11.70%
Insiders
0.05% Mutual Funds
4.85% Other Institutional Investors
83.40% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
CNTB FAQ
What was Connect Biopharma Holdings’s price range in the past 12 months?
Connect Biopharma Holdings lowest stock price was $0.68 and its highest was $2.66 in the past 12 months.
What is Connect Biopharma Holdings’s market cap?
Currently, no data Available
When is Connect Biopharma Holdings’s upcoming earnings report date?
Connect Biopharma Holdings’s upcoming earnings report date is Mar 27, 2025 which is in 121 days.
How were Connect Biopharma Holdings’s earnings last quarter?
Connect Biopharma Holdings released its earnings results on Sep 05, 2024. The company reported $0.137 earnings per share for the quarter, beating the consensus estimate of -$0.2 by $0.337.
Is Connect Biopharma Holdings overvalued?
According to Wall Street analysts Connect Biopharma Holdings’s price is currently Undervalued.
Does Connect Biopharma Holdings pay dividends?
Connect Biopharma Holdings does not currently pay dividends.
What is Connect Biopharma Holdings’s EPS estimate?
Connect Biopharma Holdings’s EPS estimate is -$0.32.
How many shares outstanding does Connect Biopharma Holdings have?
Connect Biopharma Holdings has 55,254,032 shares outstanding.
What happened to Connect Biopharma Holdings’s price movement after its last earnings report?
Connect Biopharma Holdings reported an EPS of $0.137 in its last earnings report, beating expectations of -$0.2. Following the earnings report the stock price went up 5.042%.
Which hedge fund is a major shareholder of Connect Biopharma Holdings?
Among the largest hedge funds holding Connect Biopharma Holdings’s share is RA Capital Management. It holds Connect Biopharma Holdings’s shares valued at N/A.
---
Connect Biopharma Holdings Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$8.00 (749.26% Upside)
$8.00 (749.26% Upside)
Hedge Fund Trend
Decreased
By 3.1M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 4.3%
Last 30 Days ▼ 0.6%
Last 30 Days ▼ 0.6%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-24.18%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-15.87%
Trailing 12-Months
Company Description
Connect Biopharma Holdings
Connect Biopharma Holdings Ltd is a clinical-stage company focused on the discovery and development of next-generation immune modulators for the treatment of serious autoimmune diseases and inflammation. It has leveraged its expertise in the biology of T cell modulation to build a portfolio of drug candidates consisting of small molecules and antibodies targeting critical pathways of inflammation. Its pipeline includes CBP-201, CBP-307, CBP-174, and CBP-233.
---
CNTB Stock 12 Month Forecast
Average Price Target
$8.00
▲(749.26% Upside)
Technical Analysis
Best Analysts Covering CNTB
1 Year
1 Year Success Rate
6/16 ratings generated profit
1 Year Average Return
-19.07%
reiterated a buy rating 8 months ago
Copying Thomas Smith's trades and holding each position for 1 Year would result in 37.50% of your transactions generating a profit, with an average return of -19.07% per trade.
---